Well that was short-lived (no pun intended). Shorts sky-rocketed back to over 6%. I reckon all that's happened here is a transfer of the short position from one company to another.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
